Dutch medtech firm Scinvivo has closed an investment round of €1m to advance human trials of its cancer diagnostics innovation.
Scinvivo aims to make cancer diagnostics faster and more accurate, enabling reduction of unnecessary surgeries and improving the quality of patients’ lives.
It has developed an imaging platform based on a “forward looking OCT catheter” to visualise the human morphological tissue structure a few mm’s deep with a high resolution.
This approach fills the gap of the current image modalities and enables more precise minimal invasive surgeries and will significantly improve the diagnosis of cancer resulting in a precise personalised treatment.
Bladder cancer is chosen as the first field for the imaging platform. The urologists who reviewed the technology see this as a likely game-changer in their diagnostic routine with the potential to become the golden standard.
With its new investment, Scinvivo will develop in-human clinical trials and pursue CE certification.
The funding comes from the NextStage Early Stage Fund (NSESF), Innovatiefonds Noord-Holland, and current shareholders.
Marijn van Os, CEO of Scinvivo, said: “With this investment, we will make the first steps in the clinics and show the incredibly high resolution tissue images captured with our platform.”
Maaike de Jong, CTO of Scinvivo, added: “This investment enables us to perform first in vivo trials, to finalise our CE certification. We can now make a big step forward towards our goal of improving cancer diagnostics.”
Michel Simons, investor, and fund manager NSESF: ”Scinvivo is a diverse and experienced team, working on pioneering photonics technology, based on a sound IP position. The first market to address is bladder cancer. Being able to look into the tissue of hollow organs at near microscopic resolution, is possibly the key for the necessary improvement of diagnoses. We are happy to help with our investment and network.”
